Net income excluding share-based compensation expenses (non-GAAP) in 2012 was RMB145.5 million ($23.3 million). Both basic and diluted earnings per ADS excluding share-based compensation expenses (non-GAAP) in 2012 were RMB3.02 ($0.48).
Adjusted EBITDA (non-GAAP) was RMB376.0 million ($60.4 million) in 2012, representing a 18.1% increase from RMB318.4 million in 2011.
Share-based compensation expenses, which were allocated to related operating expense items, were RMB9.1 million ($1.1 million) in 2012, compared to RMB9.2 million in 2011.
Income tax expense in 2012 was RMB61.3 million ($9.8 million), compared to an income tax expense of RMB46.3 million in 2011. The effective tax rate for 2012 was 31% as compared to 28.1% in 2011.
As of December 31, 2012, the Company had total fixed assets valued at RMB1499.6 million ($240.7 million), cash and cash equivalents of RMB75.4 million ($12.1 million), and restricted cash of RMB284.0 million ($45.6 million).
Capital expenditures were RMB391.9 million ($62.9 million) in 2012, compared to RMB339.9 million in 2011.
As of December 31, 2012, the Company had bank credit lines totaling RMB2165.3 million (US$347.6 million), of which RMB765.5 million ($122.9 million) were utilized.
Accounts receivable was RMB213.3 million ($34.2 million) as of December 31, 2012, compared to RMB211.7 million as of September 30, 2012 and RMB244.2 million as of December 31, 2011. Days sales outstanding (DSO) was approximately 86 days in the fourth quarter of 2012 down from 101 days in the third quarter of 2012 and 192 days in the fourth quarter of 2011. The improved DSO was mainly due to the strengthened efforts during 2012 to accelerate collection from hospital partners, as well as the shorter DSO of Chang'an Hospital.During the fourth quarter of 2012, the Company repurchased 259,202 ADSs, representing 777,606 ordinary shares for a total $1.1 million, including commissio
|SOURCE Concord Medical Services Holdings Limited|
Copyright©2012 PR Newswire.
All rights reserved